DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ, Verploegen S, Labrijn AF, Salcedo T, Schuurman J, Parren PWHI, Breij ECW.
Engelberts PJ, et al. Among authors: horbach gj.
EBioMedicine. 2020 Feb;52:102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23.
EBioMedicine. 2020.
PMID: 31981978
Free PMC article.